Aprea Therapeutics (NASDAQ:APRE) Lowered to “Strong Sell” Rating by Zacks Research

Aprea Therapeutics (NASDAQ:APRE) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other equities analysts have also issued reports on APRE. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Wednesday, October 8th. HC Wainwright reduced their price objective on shares of Aprea Therapeutics from $20.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, December 18th. Two research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Aprea Therapeutics Stock Performance

Shares of NASDAQ APRE opened at $0.90 on Tuesday. The company has a 50 day simple moving average of $1.03 and a two-hundred day simple moving average of $1.40. Aprea Therapeutics has a fifty-two week low of $0.84 and a fifty-two week high of $4.65. The company has a market capitalization of $6.29 million, a price-to-earnings ratio of -0.42 and a beta of 1.44.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.36). The company had revenue of $0.00 million for the quarter. Aprea Therapeutics had a negative net margin of 2,666.46% and a negative return on equity of 88.12%. On average, analysts forecast that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

Insider Activity at Aprea Therapeutics

In related news, Director Marc Duey acquired 21,459 shares of the firm’s stock in a transaction dated Wednesday, December 10th. The shares were purchased at an average price of $1.17 per share, with a total value of $25,107.03. Following the completion of the purchase, the director directly owned 256,155 shares of the company’s stock, valued at $299,701.35. This represents a 9.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.63% of the stock is owned by company insiders.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.